Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 1998

View Archived Issues

Protein farnesyltransferase inhibitors disclosed by Schering-Plough

COX-2 inhibitors under study at Abbott

Interneuron: FY 1997 highlights

New carbapenems in development at Takeda

New antifungal antibiotic TKR-842 from Takara Shuzo

PLA2 inhibitors described by Santen

BioChem Pharma/Scriptgen conclude licensing and equity agreements

Yamanouchi: Six-month 1998 highlights

Efficacy of muscle relaxant established in preclinical models

CoCensys and MGH expand license for migraine treatment technology

Company Profile: Shaman

ABX-IL-8 slated to enter clinical testing

Heparinase III efficacy established in preclinical model

New vitamin D conjugates disclosed by Clarion

New NMDA/AMPA antagonists synthesized at Merck & Co.

Selective dopamine D3 ligands revealed by Neurogen

New AIDS treatment candidates disclosed by Vertex

New tachykinin antagonists from Schering-Plough

Arris acquisition of Sequana nears completion

FDA clears Optison

Bayer announces copromotion agreement for cerivastatin

Efficacy of recombinant hirudin demonstrated in patients with DIC

Vasoflux preclinical data presented at major hematology congress

Phase II results presented for BB-10010

Flocor enters phase I for ACS

Vical receives patent protection for lipid-mediated DNA vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...